Redx Oncology, a spin-out of Liverpool drug discovery company Redx Pharma, has been launched.
The cancer research has been backed with £5.9m of cash from the government’s Regional Growth Fund, plus investment from corporate finance boutique Acceleris.
Redx Oncology starts life with a five-year programme based around Redx Pharma’s existing pipeline of research cancer drugs. These cover a wide variety of cancer types, and are designed to deliver a flow of experimental drugs for progression into human clinical trials.
Derek Lindsay, managing director of Redx Oncology, said: “Liverpool has a highly respected reputation in cancer care. The Liverpool Cancer Research UK Centre along with the University of Liverpool and the Royal Liverpool Hospital provide a rich environment for developing new remedies against cancer.
“We believe that our new Oncology R&D; centre will provide an important new resource in the challenge of improving the patient experiences and outcomes with this disease.”
The Redx Oncology team consists of chemists, analytical scientists, biology scientists, administration staff and up to 24 trainees.
Max Steinberg, chief executive of Liverpool Vision, added: “The expansion of Redx is a powerful statement of intent in respect of Liverpool’s ambitions in Bio sciences and we wish the team at Redx Oncology every success with growing the business and contributing to Liverpool’s reputation as a centre of excellence for cancer research.”